2021RNDS connect. care. cure.™

Acute Disseminated Encephalomyelitis

Cynthia Wang, MD

October 8, 2021

2021 Rare Neuroimmune Disorders Symposium

Disclosures

- I received the James T. Lubin Clinician-Scientist Fellowship Award from the Siegel Rare Neuroimmune Association
- I will be discussing off-label use of therapies

Case Presentation

- 5-year-old previously healthy boy
- Developed a posterior headache, right eye blurry vision, and vomiting over 2-3 weeks
- Presented to local ER where physical examination and laboratory studies were unremarkable except for a positive SARS-CoV-2 RNA PCR nasopharyngeal swab
- His symptoms were attributed to this illness and the patient was discharged home




Case Presentation


- Returned to ED for continued headache symptoms
- Tested positive again for SARS-CoV-2
- Neurological exam was reportedly unremarkable, irritability was attributed to headaches
- MRI brain and spinal cord imaging were obtained



T2 FLAIR T1 post-gadolinium




What is ADEM?




- Acute disseminated encephalomyelitis
- Sudden and widespread inflammation of the brain and spinal cord
- Leads to myelin injury within the central nervous system and abnormal functioning of brain (encephalopathy)

Epidemiology

- Primarily affects children
- Average age of onset around 4-8 years
- 3-6 cases per million children a year
- Slight male predominance
- More common in winter and in locations further from the equator
- Preceded by an acute illness 50-80% of the time





Terminology

Encephalopathy

Brain dysfunction causing changes in thinking or level of alertness

Encephalitis

Inflammation of the brain as evidenced by neuroimaging, spinal fluid, or tissue biopsy

Infectious

Encephalitis directly caused by microorganisms

Autoimmune

Encephalitis driven by an immune response

Immune response against tumor/cancer

Paraneoplastic


ADEM

Abnormal MRI brain, blood/spinal fluid studies

Abnormal EEG, neurological exam

Clinical Presentation

- Acute illness 1-2 weeks before
- Can have fever, headache, nausea 3-4 days before neurological symptoms
- Presenting symptoms depend where inflammation occurs
 - <u>Brain</u> → Irritability, confusion, sleepiness, coma, incoordination, gait problems
 - <u>Spine</u> → Weakness, numbness, paralysis of limbs
 - Optic nerve and cranial nerves → eye pain, blurry vision, double vision, facial weakness




Examples of ADEM on brain imaging

Large, diffuse white matter lesions


Smaller, more defined white matter lesions

Gray matter lesions (thalamus, basal ganglia)


Hemorrhagic lesions



Tissue biopsy



- Immune cells (macrophages and lymphocytes) gather around veins in the white matter
- Recognize and injure myelin and myelin-producing cells (oligodendrocytes)
- Severe presentations with hemorrhage and necrosis



Diagnostic Criteria (IPMSSG, 2013) A <u>first polyfocal</u>, clinical, CNS event with presumed <u>inflammatory</u> demyelinating cause

Encephalopathy NOT explained by fever, systemic illness, or postictal symptoms


Brain MRI is abnormal during the acute (3 month) phase

- Diffuse, poorly demarcated, large (>1-2cm) lesions
- Predominantly involving cerebral white matter
- Deep gray matter lesions in thalamus or basal ganglia can be present

<u>No NEW</u> clinical or MRI findings emerge 3 months or more after onset

Laboratory Studies

- Serum (blood)
 - Test for antibodies associated with CNS demyelination
 - Myelin oligodendrocyte glycoprotein (MOG), Aquaporin-4 (AQP4)
 - Test for infections, metabolic disturbances
 - Assess vitamin D level
- Cerebrospinal fluid
 - Increased WBCs in 29-85% of cases
 - Elevated protein in 17-48% of cases
 - Rare to see oligoclonal bands
 - May have elevated opening pressure





Additional studies

- EEG
 - May show diffuse slowing (88%) or focal slowing and spikes (25%)
- Rule out mimics
 - Infectious meningoencephalitis, tumor, stroke, vasculitis, leukodystrophy, mitochondrial disorders, NMOSD, MS





Acute Treatment

- No large scale, prospective, randomized controlled clinical trials
- 3-5 days of high dose intravenous corticosteroids
 - methylprednisolone 10-30 mg/kg/day
 - dexamethasone 1-2 mg/kg/day
- Therapeutic plasma exchange (PLEX) for 5-7 sessions
- Intravenous immunoglobulin (IVIG), 2 grams/kg divided over 2-5 days
- Followed by oral corticosteroid taper
 - prednisone 1 mg/kg/day, taper over 4-6 weeks



Hospital course

- May spend 1-3 weeks in the hospital and rehabilitation
- 25% will require ICU level care (75% of whom are on ventilator)
- Supportive care for breathing, seizures, cerebral edema
- Once able to tolerate, can initiate therapy (PT, OT, ST) to help with neurological recovery



Prognosis

- Up to 3% mortality
- Often marked improvement within 30 days
- Follow-up MRI in 3-4 months can show complete or partial resolution of lesions
- Cognitive recovery takes longer and can be incomplete; fatigue may persist
- May not have normal rates of white matter and gray matter growth
- Up to 1/3 with recurrent attacks (often MOG positive)
- Epilepsy uncommon (0-16%, often MOG positive)



RECOVERY




Relapsing or Multiphasic ADEM

- Monophasic ADEM
 - A <u>single</u> ADEM episode with no further demyelinating events or new MRI lesions outside the acute three-month period after onset
- Multiphasic ADEM
 - <u>Two</u> episodes of ADEM separated by at least three months in time.
 - The second event can involve the same or new symptoms, signs or MRI lesions compared with the first event.
 - This diagnosis is limited to two episodes of ADEM.
 - <u>Three</u> or more suggest ultimate diagnosis of <u>MS, NMO, or other</u> <u>disorder</u>

Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease (MOGAD)

- MOG is a protein expressed on myelin and myelin producing cells
- Common cause of ADEM and acute demyelination in children
- Can also affect the optic nerves, spinal cord, and gray matter of the brain
- Relapse is possible, and risk may be related to persistent MOG antibody production



Supporting Recovery from ADEM

- Comprehensive neuropsychological testing
- School Accommodations
- Cognitive and Behavioral therapies
- Follow-up of neuropsychiatric symptoms
- Monitor for relapses
- Provide immunosuppressive therapy when appropriate





